Towards a standard benchmark for phenotype-driven variant and gene prioritisation algorithms: PhEval - Phenotypic inference Evaluation framework

PhEval and the standardised test corpora solve the issues of patient data availability and experimental tooling configuration when benchmarking and comparing rare disease VGPAs. By providing standardised data on patient cohorts from real-world case-reports and controlling the configuration of evaluated VGPAs, PhEval enables transparent, portable, comparable and reproducible benchmarking of VGPAs. As these tools are often a key component of many rare disease diagnostic pipelines, a thorough and standardised method of assessment is essential for improving patient diagnosis and care.

Authors

Institutions

Publication Details

Journal
BMC Bioinformatics
Published
2025-03-22
DOI
https://doi.org/10.1186/s12859-025-06105-4
Citations
5
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
9.09
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Towards a standard benchmark for phenotype-driven variant and gene prioritisation algorithms: PhEval - Phenotypic inference Evaluation framework

Daniel Korn, Chris Mungall, Nikolaos M. Marinakis, Damian Smedley et al.
5 citations
BMC Bioinformatics
Genomics and Rare Diseases
9.09
article

Towards a standard benchmark for phenotype-driven variant and gene prioritisation algorithms: PhEval - Phenotypic inference Evaluation framework

Daniel Korn, Chris Mungall, Nikolaos M. Marinakis, Damian Smedley, Katherina G Cortes, Nomi L. Harris, Aaron Odell, Nicolas Matentzoglu, Vinícius de Souza, David Osumi-Sutherland, Melissa Haendel, Julius O.B. Jacobsen, James Alastair McLaughlin, Yasemin Bridges, Peter N. Robinson
article en
5 citations

Abstract

PhEval and the standardised test corpora solve the issues of patient data availability and experimental tooling configuration when benchmarking and comparing rare disease VGPAs. By providing standardised data on patient cohorts from real-world case-reports and controlling the configuration of evaluated VGPAs, PhEval enables transparent, portable, comparable and reproducible benchmarking of VGPAs. As these tools are often a key component of many rare disease diagnostic pipelines, a thorough and standardised method of assessment is essential for improving patient diagnosis and care.

BMC BioinformaticsVol. 26(1)
University of North Carolina at Chapel Hill (US), European Bioinformatics Institute (GB), Lawrence Berkeley National Laboratory (US), Queen Mary University of London (GB), National and Kapodistrian University of Athens (GR), Wellcome Sanger Institute (GB), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), William Harvey Research Institute (GB), University of Colorado Anschutz Medical Campus (US)
Openalex Percentile: Top 2%
Genomics and Rare Diseases
9.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.